Literature DB >> 32538566

[Long-term effectiveness of "West China Classification" guided surgical treatment of desmoid-type fibromatosis in shoulder girdle].

Sisi Zhou1, Fan Tang1, Li Min1, Yi Luo1, Yong Zhou1, Hong Duan1, Chongqi Tu1.   

Abstract

OBJECTIVE: To evaluate the long-term effectiveness of patients received surgical treatment under the guidance of "West China Classification" of desmoid-type fibromatosis (DTF) in the shoulder girdle.
METHODS: The clinical data of 32 patients with DTF in the shoulder girdle admitted between June 2003 and December 2016 were retrospectively analyzed, including 14 males and 18 females, aged 14-56 years with an average age of 36.8 years. The maximum diameter of the tumor was 7-19 cm, with an average of 11.1 cm. According to the "West China Classification" of DTF in the shoulder girdle, there were 4 cases of region Ⅰ, 3 cases of region Ⅱ, 6 cases of region Ⅲ, 3 cases of region Ⅳ, 5 cases of regions Ⅰ+Ⅱ, 5 cases of regions Ⅱ+Ⅲ, and 6 cases of regions Ⅰ+Ⅱ+Ⅲ. In addition, the involvement of blood vessels and nerves was also taken into consideration for choosing a surgical approach. Finally, 12 cases were operated via anteroposterior approach (group A), 14 via posterior approach (group B), and 6 via combined anterior-posterior approach (group C). The 1993 Musculoskeletal Tumor Society (MSTS93) score (including pain, limb function, satisfaction, hand position, hand flexibility, and lifting ability), Japanese Orthopedic Association (JOA) score, range of motion (ROM) of shoulder joint (including flexion, extension, abduction, and adduction), and complications of patients in the 3 groups were recorded and compared.
RESULTS: All the 32 patients were followed up 30-190 months, with an average of 94.6 months. At last follow-up, complications occurred in 5 cases (15.6%), including 2 cases (16.6%) in group A, 2 (14.3%) in group B, and 1 (16.6%) in group C. There was no significant difference in the incidence of complications among the 3 groups ( P=1.000). Tumor recurrence occurred in 5 (15.6%) cases, including 1 (8.3%) case in group A, 2 (14.3%) in group B, and 1 (16.6%) in group C. No significant difference was found in the recurrence rate among the 3 groups ( P=1.000). At last follow-up, MSTS93 score of pain, limb function, satisfaction, hand flexibility, and hand position in groups A and B were significantly better than those in group C ( P<0.05), even though no significant difference existed between group A and group B ( P>0.05). The lifting ability score in group C was significantly lower than in group A ( P<0.05), and no significant difference was found between other groups ( P>0.05). The JOA score and flexion, extension, abduction, and adduction activities of shoulder in groups A and B were significantly better than those in group C ( P<0.05). The extension activity in group A was significantly better than that in group B ( P<0.05), the flexion activity in group B was significantly better than that in group A ( P<0.05). There was no significant difference in other indexes between groups A and B ( P>0.05).
CONCLUSION: Taking a rational approach to fully expose and completely remove the tumor is the key point of surgical treatment for patients with DTF in the shoulder girdle. At the same time, preservation of vital structures and reconstruction of soft tissues should also be taken into consideration. Overall, surgical treatment under the guidance of "West China Classification" of DTF in the shoulder girdle has achieved satisfactory long-term effectiveness.

Entities:  

Keywords:  Shoulder girdle; desmoid-type fibromatosis; long-term effectiveness; surgical approach

Mesh:

Year:  2020        PMID: 32538566      PMCID: PMC8171535          DOI: 10.7507/1002-1892.201912143

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  29 in total

1.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Large desmoid-type fibromatosis of the shoulder girdle: operative approach selection and clinic outcome.

Authors:  Fan Tang; Li Min; Rui Yin; Wenli Zhang; Yong Zhou; Yi Luo; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Int Orthop       Date:  2015-01-21       Impact factor: 3.075

3.  Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

Authors:  N Penel; A Le Cesne; B N Bui; D Perol; E G Brain; I Ray-Coquard; C Guillemet; C Chevreau; D Cupissol; S Chabaud; M Jimenez; F Duffaud; S Piperno-Neumann; L Mignot; J-Y Blay
Journal:  Ann Oncol       Date:  2010-07-09       Impact factor: 32.976

4.  Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution.

Authors:  Wei-Gen Zeng; Zhi-Xiang Zhou; Jian-Wei Liang; Hui-Rong Hou; Zheng Wang; Hai-Tao Zhou; Xing-Mao Zhang; Jun-Jie Hu
Journal:  Tumour Biol       Date:  2014-05-02

Review 5.  Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions.

Authors:  N Eastley; T McCulloch; C Esler; I Hennig; J Fairbairn; A Gronchi; R Ashford
Journal:  Eur J Surg Oncol       Date:  2016-02-19       Impact factor: 4.424

6.  Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors.

Authors:  Adelaide M Carothers; Hira Rizvi; Rian M Hasson; Yvonne I Heit; Jennifer S Davids; Monica M Bertagnolli; Nancy L Cho
Journal:  Cancer Res       Date:  2011-11-17       Impact factor: 12.701

7.  Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence.

Authors:  Patrick B Garvey; Justin H Booth; Donald P Baumann; Kathy A Calhoun; Jun Liu; Raphael E Pollock; Charles E Butler
Journal:  J Am Coll Surg       Date:  2013-06-29       Impact factor: 6.113

8.  Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.

Authors:  Victor Manuel Villalobos; Francis Hall; Antonio Jimeno; Lia Gore; Kenneth Kern; Rossano Cesari; Bo Huang; Jeffrey T Schowinsky; Patrick Judson Blatchford; Brianna Hoffner; Anthony Elias; Wells Messersmith
Journal:  Ann Surg Oncol       Date:  2017-09-08       Impact factor: 5.344

9.  Long-term outcomes of 47 patients with aggressive fibromatosis of the chest treated with surgery.

Authors:  D Ma; S Li; R Fu; Z Zhang; Y Cui; H Liu; Y Meng; W Wang; Y Bi; Y Xiao
Journal:  Eur J Surg Oncol       Date:  2016-06-29       Impact factor: 4.424

10.  The management of extra-abdominal desmoid tumours.

Authors:  Amit Duggal; Ian C Dickinson; Scott Sommerville; Price Gallie
Journal:  Int Orthop       Date:  2004-05-28       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.